Start with practical, low-risk steps: clean the area gently with soap and water, avoid topical irritants, and avoid scratching
Beginning in 2026, markers of semaglutide and tirzepatide are being monitored under the WADA Monitoring Program to track potential misuse in and out of competition
Semaglutide is known to frequently cause gastrointestinal issues, including nausea, vomiting, and diarrhea, which can limit its tolerability for some patients
Licensed healthcare professionals must evaluate each patient individually before prescribing this weight loss treatment
News provided by MyNetDiary Inc May 05, 2026, 09:39 ET GLP-1 Companion combines injection reminders, protein tracking, digestive symptom logging, and meal planning inside MyNetDiary Premium